Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;18(2):85-86.
doi: 10.1038/s41575-020-00406-0.

Nonalcoholic fatty liver disease: another leap forward

Manal F Abdelmalek  1
Affiliations
Review

Nonalcoholic fatty liver disease: another leap forward

Manal F Abdelmalek. Nat Rev Gastroenterol Hepatol. 2021 Feb.

Abstract

In 2020, there have been substantial advances in nonalcoholic fatty liver disease mechanisms, diagnostics and treatment. Key developments include the identification of a cellular and tissue signature to provide new insights into pathophysiology, advancements in non-invasive diagnostics and publication of interim results of the first phase III trial to demonstrate improvement in hepatic fibrosis.

PubMed Disclaimer

Conflict of interest statement

Research funding (paid to institution): Allergan, Intercept, Madrigal, Viking, Genfit, Gilead, Galactin, Novo-Nordisk, Novartis, NGM Bio, Bristol-Myers Squibb, Genentech, Celgene, Poxel, Durect, Enyo, Inventiva, Enanta, Target Pharma, Boerhinger-Ingelheim, Hanmi. Advisory/consultancy: Allergan, Intercept, Madrigal, Novo-Nordisk, NGM Bio, Bristol-Myers Squibb, Inventiva, Boerhinger-Ingelheim, Promethera. Speaker’s bureaus: Intercept, Clinical Care Options, Fishawack, Inc, Chronic Liver Disease Foundation, Medscape.

Figures

None
Laura Marshall/Springer Nature Limited
See this image and copyright information in PMC

References

    1. Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
    1. Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043. - DOI - PMC - PubMed
    1. Davison BA, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 2020 doi: 10.1016/j.jhep.2020.06.025. - DOI - PubMed
    1. Segovia-Miranda F, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat. Med. 2019;25:1885–1893. doi: 10.1038/s41591-019-0660-7. - DOI - PMC - PubMed
    1. Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7. - DOI - PubMed

MeSH terms